29
Jul

After Sarepta Therapeutics’ former head scientist blamed his swift ouster on “serious disagreements” with CEO Chris Garabedian, the company has moved to limit its chief executive’s power, according to a report, especially when it comes to meetings with the FDA over the biotech’s much-scrutinized lead drug.

…read more

Source: Sarepta’s boardroom intrigue clouds a promising drug’s future

    

0 No comments